Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2006 Mar;116(3):769-74. Epub 2006 Feb 23.

Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154.

Author information

1
Transplantation Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA.

Abstract

CD154 is a cell surface molecule expressed on activated T cells that binds to CD40, an activating molecule on APCs. Its blockade has been shown to prevent allograft rejection, presumably by interrupting interactions between T cells and APCs. It is known that activated human platelets express and shed CD154 and can induce APC activation and other immune processes in vitro. Here we show that platelet-derived CD154 is sufficient to initiate cardiac allograft rejection independent of any cellular source of this molecule. CD154-KO mice reject cardiac allografts after receiving CD154-expressing human platelets or recombinant CD154 (rCD154) trimers. Treatment with the human CD154-specific mAb 5c8 specifically prevents this induced rejection. Soluble trimers, but not platelets, induce rejection when infused temporally remote from the surgical procedure, suggesting that surgically induced platelet activation is required for CD154 release. Allograft rejection can thus be instigated by activated platelets through CD154. These data implicate platelets as a proximal component of acquired alloimmunity, providing insight into the mechanisms of allograft rejection and the physiological response to trauma in general.

PMID:
16498500
PMCID:
PMC1378189
DOI:
10.1172/JCI27155
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center